Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRE | P78334 | 2/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292600 | 1.00 | SIRT6 (0.37) | SIRT6SMN1; SMN2MAPK1GABRPGABRD | |
| SCHEMBL26765951 | 0.85 | GABRP (0.38) | SIRT6SMN1; SMN2MAPK1GABRPGABRD | |
| SCHEMBL533490 | 0.82 | KMT2A (0.46) | SIRT6SMN1; SMN2GABRPGABRDGABRA1 | |
| SCHEMBL22890162 | 0.82 | LRRK2 (0.36) | SIRT6LRRK2TDP1 | |
| SCHEMBL20331043 | 0.82 | SIRT6 (0.47) | SIRT6SMN1; SMN2NNMTNAPRT | |
| SCHEMBL29465796 | 0.82 | KMT2A (0.46) | SIRT6SMN1; SMN2GABRPGABRDGABRA1 | |
| SCHEMBL3714762 | 0.80 | KDM4E (0.51) | MAPK1ALDH1A1KDM4EHPGDMAPT | |
| SCHEMBL7454261 | 0.80 | SCN10A (0.40) | SMN1; SMN2NNMT | |
| SCHEMBL16712886 | 0.80 | GABRP (0.37) | SIRT6GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL31278662 | 0.80 | SCN10A (0.40) | SMN1; SMN2NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYA THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| EP-4482831-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | Satya Therapeutics, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-118696034-A | Novel bicyclic compounds as RAD51 inhibitors | 萨提亚疗法股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2023161782-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | SATYARX PHARMA INNOVATIONS PVT LTD (IN) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023051628-A1 | SOS1 INHIBITORS HAVING PYRIDO SIX-MEMBERED RING STRUCTURE | 上海海和药物研究开发股份有限公司 | 2023-04-06 | — | — | WO | disclosed |
| EP-3066093-B9 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3066093-B9 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3066093-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-3066093-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9718804-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2015069594-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
| EP-2342190-A1 | BICYCLIC KINASE INHIBITORS | Novartis AG (CH) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010026121-A1 | BICYCLIC KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145601-A1 | NOVEL BICYCLIC COMPOUNDS AS RAD51 INHIBITORS | RAD51, ERCC4, ERCC2 | SIRT6 3299/4885SMN1; SMN2 1118/4885MAPK1 1643/4885 |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | SIRT6 2774/4885SMN1; SMN2 1444/4885MAPK1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.